氯化[4-[(4-氯苯基)氰基甲基]-5-氯-m-苯甲基]铵 | 222631-87-0

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡唑并嘧啶类
• 中文名称: 氯化[4-[(4-氯苯基)氰基甲基]-5-氯-m-苯甲基]铵
• 英文名称: (1R)-1-C-(5-amino-7-hydroxypyrazolo[4,3-d]pyrimidin-3-yl)-1,4-imino-1,2,4-trideoxy-D-erythro-pentitol
• 英文别名: 5-amino-3-[(2R,4S,5R)-4-hydroxy-5-(hydroxymethyl)pyrrolidin-2-yl]-2,6-dihydropyrazolo[4,3-d]pyrimidin-7-one
• CAS: 222631-87-0
• 化学式: C₁₀H₁₄N₆O₃
• 分子量: 266.26
• InChiKey: DDFHBSMYCXRGGK-WDCZJNDASA-N

物化性质

• 密度：
  2.21±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  -2.4
• 重原子数：
  19
• 可旋转键数：
  2
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.5
• 拓扑面积：
  149
• 氢给体数：
  6
• 氢受体数：
  5

文献信息

• Inhibitors of nucleoside metabolism
  申请人：——

  公开号：US20020061898A1

  公开（公告）日：2002-05-23

  The present invention provides novel nucleoside-analogue compounds that are effective inhibitors of purine nucleoside phosphorylase (PNP), purine phosphoribosyltransferases (PPRT), and/or nucleoside hydrolases. Also provided are tautomers, esters, prodrugs, and pharmaceutically-acceptable salts of the compounds disclosed herein. The present invention further provides the use of these compounds as pharmaceuticals. The present invention also discloses pharmaceutical compositions containing these compounds. Finally, the present invention provides processes for preparing these compounds.

  本发明提供了新型核苷类似物化合物，它们是嘌呤核苷酸磷酸酶（PNP）、嘌呤磷酸核糖转移酶（PPRT）和/或核苷水解酶的有效抑制剂。此外，还提供了这些化合物的互变异构体、酯、前药和药学上可接受的盐。本发明进一步提供了这些化合物作为药物的用途。本发明还揭示了含有这些化合物的制药组合物。最后，本发明提供了制备这些化合物的过程。
• Inhibiting T-cell proliferation
  申请人：——

  公开号：US20030114466A1

  公开（公告）日：2003-06-19

  T-cell inhibition proliferation in a mammalian host by administering effective amounts of 2′-deoxyguanosine and/or prodrugs thereof; and certain PNP inhibitors.

  通过施用有效量的 2′-脱氧鸟苷和/或其原药，抑制哺乳动物宿主中 T 细胞的增殖；以及某些 PNP 抑制剂。
• Enhancing the efficacy of reverse transcriptase and dna polymerase inhibitors (nucleoside analogs) using pnp inhibitors and/or 2'-deoxyguanosine and/or prodrug thereof
  申请人：Bantia Shanta

  公开号：US20050250728A1

  公开（公告）日：2005-11-10

  The efficacy of reverse transcriptase and DNA polymerase inhibitors (nucleoside analogs) in a mammalian host is enhanced by administering an effective amount of PNP inhibitor of prodrug of PNP inhibitor and/or an effective amounts of 2′-de-oxyguanosine and/or prodrugs thereof.

  通过施用有效量的 PNP 抑制剂原药和/或有效量的 2′-脱氧鸟苷和/或其原药，可提高逆转录酶和 DNA 聚合酶抑制剂（核苷类似物）对哺乳动物宿主的疗效。
• INHIBITORS OF NUCLEOSIDE METABOLISM
  申请人：ALBERT EINSTEIN COLLEGE OF MEDICINE OF YESHIVA UNIVERSITY

  公开号：EP1023308B1

  公开（公告）日：2005-09-07
• COMPOSITIONS FOR TREATING OR PREVENTING OBESITY AND INSULIN RESISTANCE DISORDERS
  申请人：President and Fellows of Harvard College

  公开号：US20170216272A1

  公开（公告）日：2017-08-03

  Provided herein are methods and compositions for modulating the activity or level of a sirtuin, thereby treating or preventing obesity or an insulin resistance disorder, such as diabetes in a subject. Exemplary methods comprise contacting a cell with a sirtuin activating compound or an inhibitory compound to thereby increase or decrease fat accumulation, respectively.